Pharming Group N.V.
P.O. Box 451
AL Leiden
2300
Tel: 31-0-71-524-7400
Fax: +31-0-71-521-6507
Website: http://www.pharming.com/
Email: pharming@pharming.com
317 articles about Pharming Group N.V.
-
Pharming Group reports fourth quarter and full year 2023 financial results
3/14/2024
Pharming Group N.V. presents its preliminary financial report for the three months and full year ended December 31, 2023.
-
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
2/29/2024
Pharming Group N.V. confirms it will report its preliminary fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.
-
Pharming Group to participate in February 2024 investor conferences
2/8/2024
Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of February.
-
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
12/13/2023
Pharming Group N.V. announces the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies beyond activated phosphoinositide 3-kinase delta syndrome.
-
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
11/21/2023
Pharming Group N.V. announces that the first patient has been dosed in its Phase III pediatric clinical trial evaluating a new pediatric formulation of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, in children ages one to six years, with activated phosphoinositide 3-kinase delta syndrome.
-
Pharming Group to participate in November 2023 investor conferences
11/1/2023
Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of November:.
-
Pharming Group reports third quarter 2023 financial results
10/26/2023
Pharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2023.
-
Pharming Group to report third quarter 2023 financial results on October 26
10/12/2023
Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. confirms it will report its preliminary third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023.
-
Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders
9/25/2023
Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. announces that the Extraordinary General Meeting of Shareholders has adopted all proposals on the EGM agenda.
-
Pharming Group to participate in September 2023 investor conferences
8/24/2023
Pharming Group N.V. announces that Pharming's management will participate in the following investor conferences in the U.S. in the month of September.
-
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan
8/9/2023
Pharming Group N.V. announces that the first patient has been enrolled in its Phase III clinical trial in Japan evaluating leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients 12 years of age and older.
-
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board
7/18/2023
Pharming Group N.V. announces that the Board of Directors has nominated Dr. Richard Peters to become Pharming's new Chairman.
-
Pharming Group to report second quarter and first half 2023 financial results on August 3
7/13/2023
Pharming Group N.V. confirms it will report its preliminary second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.
-
Pharming announces sale of priority review voucher
6/1/2023
Pharming Group N.V. announces that it has entered into a definitive agreement with Novartis Pharma A.G. to sell its Rare Pediatric Disease Priority Review Voucher to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.
-
Pharming Group to attend the following Investor Conferences in June 2023
5/25/2023
Pharming Group N.V. announces that Pharming's management will attend the following investor conferences in the month of June.
-
Pharming Group reports financial results for the first quarter of 2023
5/11/2023
Pharming Group N.V. presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023.
-
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.
4/11/2023
Pharming Group N.V. announces the first commercial shipments of Joenja® to patients in the United States.
-
Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days
3/30/2023
Pharming Group N.V. announces that Pharming's Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will attend the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days, April 3 - 4, 2023 in New York.
-
The FDA is expected to make decisions on Emergent BioSolutions' sNDA for OTC Narcan and Roche's Polivy in frontline DLBCL.
-
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
3/24/2023
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.